Amyloid Beta-Protein Products Available from Peptides International

Amyloid b-Protein and Related Peptides

Alzheimer's Disease (AD)

Alzheimer's Disease (AD) is a progressive, neurodegenerative disease characterized by memory loss, language deterioration, impaired visuospatial skills, poor judgment, indifferent attitude, but preserved motor function.

• First described in 1906 by German physician Dr. Alois Alzheimer
• Top ten cause of death for people over 65 in the US, most commonly due to infection
• Currently no cure or prevention
• Duration of the illness may often vary from 3 to 20 years
• By 2050 14 million Americans (estimated) will be effected unless a cure or prevention is found

At Peptides International we produce Amyloid Protein fragments and peptides that are highly useful tools for research applications. Many researchers in our field are actively pursuing a cure and/or prevention for AD and are working on understanding this disease. The information about our products below describes some recent research available in prominent scientific journal publications and these research tools are commercially available from Peptides International. The specific role of these peptides in AD is not completely understood at this time. As with all of our products these are sold for research purposes only and not for use in humans. We hope our customers and colleagues will soon be successful at unraveling this puzzle and bringing a cure to so many people around the world who are in desperate need.

Below are a few resource sites for AD patients and their families
and friends who wish to learn more about this disease

National Institute of Neurological Disorders and Stroke
NINDS Alzheimer's Disease Information Page

Alzheimer's Association

Alzheimer's Disease Education & Referral Center

Below is a link to a resource site for AD researchers

Alzheimer's Research Forum: Networking for a Cure

Amyloid b-Proteins and Related Research Product Features

Amyloid b-protein (Ab) has been found as insoluble, fibrillar deposits in the brains of Alzheimer’s disease patients. Such deposits are also believed to play a role in prion disease, Huntington's disease, diabetes and rheumatoid arthritis. Removal of factors promoting this deposition has been shown to restore normal tissue function implicating viable prevention routes to these diseases. Inhibition of fibrill formation or disruption of plaque formation is thought to be paramount in the development of a treatment for such diseases.

NEW Membrane Permeable Inhibitor of Ab (1-40) Fibrillogenesis

Recently Gordon and coworkers have descibed a peptide with alternating N-methyl amino acids that inhibits b-amyloid (1-40) fibrillogenesis (1). The use of N-methyl amino acids has been previously described as a means to control peptide or protein aggregation through disruption of hydrogen bonding and secondary structure formation. In 2002 an Ab (1-40) fibrillogenesis inhibitor, Ac-Lys-N-Me-Leu-Val-N-Me-Phe-Phe-NH₂ (or Ac-K(Me)LV(Me)FF-NH₂), (product code PAB-3631-PI) was reported by the same group and found to be membrane permeable. The sequence is derived from the hydrophobic core of Ab40 (Ab16-20). This hydrophobic analog possesses alternating N-methyl amino acids and was surprisingly highly water soluble considering Ac-KLVFF-NH₂ without N-methylation is only sparingly soluble. This peptide not only inhibits fibrill formation it also disrupts preformed fibrils. Both applications should prove to be highly useful for probing structural features of this class and as a potential therapeutic target for disruption of b-sheet formation.

1. D.J. Gordon, K.L. Sciarretta, and S.C. Meredith, Biochemistry, 40, 8237 (2001).
2. D.J. Gordon, R. Tappe, and S.C. Meredith, J. Pep. Res., 60(1), 37-55 (2002).

NEW b-sheet breaker peptide iAb5p Now Available

Soto et al. reported the design and synthesis of a b-sheet breaker peptide iAb5, LPFFD (1) (product code PAB-3632-PI). The hydrophobic region of the N-terminal domain of amyloid b-protein (residues 17-20, LVFF) was selected as the model sequence and proline, well known to disrupt b-sheet formation, was incorporated along with a charged residue to aid in solubility. This 5-residue peptide has been found to block amyloid b-fibrillogenesis and is a potential new basis for prevention of amyloidosis in Alzheimer’s patients.

1. Soto, C., Sigurdsson, E. M., Morelli, L., Kumar, R. A., Castaño, E. M. and Frangione B. Nature Medicine 4, 822 (1998).

CODE	COMPOUND	QTY	USD
PAB-3637-PI NEW!	Ac-Leu-Pro-N-Me-Phe-Phe-Asp-NH₂ iAb5p-A1, Ac-LP-(NMe)-FFD-NH₂ Ab(1-42) Fibrillogenesis Inhibitor, iAb5p-A1	5 mg	95
PAB-3631-PI NEW!	Ac-Lys-N-Me-Leu-Val-N-Me-Phe-Phe-NH₂ Ac-K(Me)LV(Me)FF-NH2 Membrane Permeable Inhibitor of Ab(1-40) Fibrillogenesis D.J. Gordon, R. Tappe, and S.C. Meredith, J. Pep. Res., 60(1), 37-55 (2002). D.J. Gordon, K.L. Sciarretta, and S.C. Meredith, Biochemistry, 40, 8237 (2001).	1 mg 5 mg	65 245
PAB-3632-PI NEW!	Ac-Leu-Pro-Phe-Phe-Asp-NH₂ Beta-Sheet Breaker Peptide iAB5p (M.W. 678.89) C₃₅H₄₆N₆O₈ Ab(1-42) Fibrillogenesis Inhibitor, iAB5p	5 mg	85
PAB-4370-v	Amyloid b-Protein (Human, 1-43) (Trifluoroacetate Form) Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln- Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly- Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Thr (M.W. 4615.1) C₂₀₇H₃₁₈N₅₆O₆₂S Major Plaque Component in Alzheimer’s Disease Purity: higher than 95% by HPLC	0.5 mg	369
PAM-4349-v	Amyloid b-Protein (Human, 1-42) (Trifluoroacetate Form) Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln- Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly- Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala (M.W. 4514.1) C₂₀₃H₃₁₁N₅₅O₆₀S Major Plaque Component in Alzheimer’s Disease Purity: higher than 95% by HPLC	0.5 mg	315
PAB-4359-v	Amyloid b-Protein (Human, 1-16) Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys (M.W. 1955.0) C₈₄H₁₁₉N₂₇O₂₈ Blocker for Plaque-Induced Microgliosis/Reducer for Brain Inflammation	0.5 mg	105
PAB-4367-v	[Pyr³]-Amyloid b-Protein (Human, 3-42) (Trifluoroacetate Form) Pyr-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu- Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile- Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala (M.W. 4309.9) C₁₉₆H₂₉₉N₅₃O₅₅S Major Plaque Component in Alzheimer’s Disease	0.5 mg	315
PAB-4358-v	b-Sheet Breaker Peptide iAb5 Leu-Pro-Phe-Phe-Asp (M.W. 637.73) C₃₃H₄₃N₅O₈ Inhibitor of Amyloid Deposition	5 mg	169
PAB-3615-PI	b-Sheet Breaker Peptide iAb5 (Bulk) H-Leu-Pro-Phe-Phe-Asp-OH (M.W. 637.73) C₃₃H₄₃N₅O₈ Inhibitor of Amyloid Deposition	25 mg	340
NEW! PAB-4379-v	Amyloid b -Protein (Human, 1-40) (HCl Form) Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln- Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly- Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val (M.W. 4329.9) C₁₉₄H₂₉₅N₅₃O₅₈S Major Plaque Component in Alzheimer’s Disease Specific Form Easily Transferrable to ß-Structure B.A. Yankner, L.K. Duffy, and D.A. Kirschner, Science, 250, 279 (1990).	0.5 mg	219
PAM-4307-v	Amyloid b-Protein (Human, 1-40) (Trifluoroacetate Form) Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln- Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly- Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val (M.W. 4329.9) C₁₉₄H₂₉₅N₅₃O₅₈S Peptide Deposited in Brain of Alzheimer’s Disease Patient Purity: higher than 95% by HPLC	0.5 mg	189
PAM-4309-v	Amyloid b-Protein (Human, 25-35) Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met (M.W. 1060.3) C₄₅H₈₁N₁₃O₁₄S	0.5 mg	47
NAB-14359-v	Amyloid b-Protein (Human, 1-16) Antiserum Amyloid b-Protein N-Terminal Specific Antiserum (Rabbit) Antiserum: lyophilized from 0.001 M Phosphate Buffer, pH=7.0 Immunogen: Amyloid b-Protein (Human, 1-16)-KLH	50 ml	259
NAB-14356-v	Amyloid b-Protein (Human, 34-40) Antiserum Amyloid b-Protein (1-40) Specific Antiserum (Rabbit) Antiserum: lyophilized from 0.001 M Phosphate Buffer, pH=7.0 Immunogen: Amyloid b-Protein (Human, 34-40)-KLH	50 ml	259
NAB-14357-v	Amyloid b-Protein (Human, 37-42) Antiserum Amyloid b-Protein (1-42) Specific Antiserum (Rabbit) Antiserum: lyophilized from 0.001 M Phosphate Buffer, pH=7.0 Immunogen: Amyloid b-Protein (Human, 37-42)-KLH	50 ml	259
NAP-14307-v	Amyloid b-Protein (Human, 1-40) Antiserum (Rabbit) Antiserum: lyophilized from 0.001 M Phosphate Buffer, pH=7.0 Immunogen: Amyloid b-Protein (Human, 1-40) (Carrier-free)	50 ml	259

Peptides International, Inc.
PO Box 24658
Louisville, Kentucky 40224 USA
Phone: 502-266-8787 or 800-777-4779 (USA and Canada)
Fax: 502-267-1FAX (1329)